The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs…

The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs…

Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including…

Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL)….

Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a partial response, meaning the size of the cancer tumour has…

Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…

Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion cohort targeting relapsed and refractory T cell lymphoma (TCL) – and…

Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater for strong investor demand. Late last week, the clinical-stage oncology…

“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing director and CEO Steven Yatomi-Clarke.